-

OM1’s PhenOM® Foundation AI Surpasses One Billion Years of Health History in Model Training

BOSTON--(BUSINESS WIRE)--OM1, a leading provider of AI-driven insights for life sciences and healthcare organizations, today announced a major milestone in the development of its groundbreaking PhenOM® Foundation Model. The model has now been trained on more than one billion years of patient health histories, representing the largest model of its kind to date.

PhenOM is a next-generation AI platform that identifies patient phenotypes and accurately predicts diagnoses, outcomes, and treatment effects at scale. By analyzing structured and unstructured data from diverse healthcare sources, the PhenOM API delivers real-time predictions on thousands of outcomes from hospitalizations to heart attacks and strokes across a wide range of diseases and populations.

“Training AI models on real-world health data at this scale opens up unprecedented opportunities to improve how we predict, diagnose, and treat disease,” said Dr. Richard Gliklich, CEO of OM1. “PhenOM is not just a model, it’s an adaptive foundation layer built on billions of clinical events, enabling intelligent healthcare applications and research across the entire ecosystem.”

In addition to predicting outcomes, the PhenOM model evaluates the safety and benefits of treatments in specific patients and subpopulations. This enables healthcare stakeholders to identify underdiagnosed or undertreated patients, improve clinical trial efficiency, and support precision health initiatives.

OM1’s innovation in AI-driven real-world evidence is underpinned by a strong and expanding intellectual property portfolio. Eight U.S. patents have been issued to date for OM1’s technologies, with a ninth patent scheduled to issue on May 20, 2025, further strengthening the company’s position as a leader in applied clinical AI. OM1 is currently working with a range of partners, including leading healthcare systems, health plans, life sciences organizations, and software companies, to integrate PhenOM into programs that target population health, value-based care, and drug development.

Meet our PhenOM experts and learn more at ISPOR 2025, booth #1500.

About OM1:

OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE.

Contacts

Media:
Kristine Christie
Vice President Marketing
kchristie@om1.com
Om1.com

OM1


Release Versions

Contacts

Media:
Kristine Christie
Vice President Marketing
kchristie@om1.com
Om1.com

More News From OM1

OM1 Rheumatoid Arthritis Dataset Rated High Quality as Cornerstone AI Partnership Speeds Future Quality Reviews

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--OM1, a leader in real-world evidence (RWE) generation and AI-driven insights for healthcare and life sciences, today announced that its Rheumatoid Arthritis (RA) specialty dataset achieved the highest quality score in an independent, AI-powered evaluation conducted by Cornerstone AI, a trusted authority in healthcare data quality. The automated evaluation measured OM1’s dataset across three key dimensions: standardization, correctness, and completeness,...

OM1 Adds a Half Million Patients to Neurology Network, Strengthening Real-World Evidence Generation and Accelerating Innovation in Neurology

BOSTON--(BUSINESS WIRE)--OM1, a leader in real-world evidence (RWE) generation and AI-driven insights for healthcare and life sciences, today announced the expansion of its Neurology Specialty Network with the addition of 500,000 patients. The network now includes over 3 million individuals with electronic health records and notes from relevant specialists, making it one of the largest and most clinically rich neurology real-world data resources available. The expansion significantly enhances O...

OM1 Appoints Hunter Lane as Chief Product Officer

BOSTON--(BUSINESS WIRE)--OM1, the leader in real-world evidence (RWE) generation and AI-driven insights for healthcare and life sciences, today announced the appointment of Hunter Lane as Chief Product Officer. In this role, Lane will lead the company’s Product and Engineering teams, overseeing the development and delivery of OM1’s rapidly growing portfolio of AI-driven evidence and outcomes solutions. “Hunter’s track record of building category-defining platforms and delivering impact at scale...
Back to Newsroom